April 29, 2024 – Abbott introduced that the U.S. Meals and Drug Administration (FDA) has permitted the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for individuals with power limb-threatening ischemia (CLTI) under: the knee (BTK). The Esprit BTK System is designed to maintain arteries open and ship a drug (Everolimus) to […]
